NCT04392609 is a clinical trial in Rectal Cancer, sponsored by Ziqiang Wang,MD.

Who is sponsoring NCT04392609?

NCT04392609 is sponsored by Ziqiang Wang,MD.

What condition does NCT04392609 study?

NCT04392609 studies Rectal Cancer, MRI.

Is NCT04392609 still recruiting?

NCT04392609 is currently status unknown. Last updated 19 May 2020.

Last reviewed 2020-05-19 · How we verify

NCT04392609

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predicting Locally Advanced Rectal Cancer Response to NCT and NCRT With MRI

Status unknown Last updated 19 May 2020

What this trial tests

trial in Rectal Cancer in 180 participants. Status unknown.

Timeline

15 January 2020

Primary endpoint
15 June 2020

15 July 2020

Quick facts

Lead sponsor	Ziqiang Wang,MD
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	180
Start date	15 January 2020
Primary completion	15 June 2020
Estimated completion	15 July 2020
Sites	1 location across China

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →
MRI — all drugs for MRI →

Sponsor

Ziqiang Wang,MD

Who can join

Eligibility, any sex, with Rectal Cancer or MRI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial was designed to to study whether there is a difference in MRI image evaluation between NCRT and NCT, and try to build a model to predict the efficacy of neoadjuvant therapy by combining multiple imaging indexes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other Ziqiang Wang,MD trials

Trials by the same sponsor.

NCT03930082 — Frailty Assessment of Patients With Gastrointestinal Surgery · unknown
NCT03826862 — Lateral Lymph Node Dissection for Middle-low Rectal Cancer · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04392609 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ziqiang Wang,MD
Last refreshed: 19 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04392609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing